Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by Michel1234on Mar 06, 2021 12:23pm
131 Views
Post# 32736288

RE:$4.91

RE:$4.91Hi Mugsy,

I also picked up a 1000 shares at 5,01$ to increase my position to 11 000 shares. It was the first time I bough more shares in 3 years. I might add more if the share price go in the range between $3 and $5.

It is very diffcult to know what is going on in LATAM and we have almost no guidance from the management. I hope we will not see a write-off in the goodvill/intangible of GBT at year-end. That would be a clear indicator that things are not going well. The timing of the acquisition was not good. The pandemic and the foreign exchange had certainly a negative impact on this acquisition and the purchase price would have been so much better in the deal would have been later. I would say that a portion of the reduction in the share price is very likely related to a real loss of value due to fundamental reasons.

A lot of people are saying Meir was right about the future of Knight. However, maybe Goodman and other significant shareholders are happy to keep the share price low until Meir sold his shares (four years after November 2019). I try to stay positive. :)

We need more deals. It is so quiet... zzz :)

Michel

<< Previous
Bullboard Posts
Next >>